http://rdf.ncbi.nlm.nih.gov/pubchem/reference/33608216

Outgoing Links

Predicate Object
contentType Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
endingPage 813
issn 1462-8902
issueIdentifier 9
pageRange 806-813
publicationName Diabetes, Obesity and Metabolism
startingPage 806
bibliographicCitation Kong AP, Yamasaki A, Ozaki R, Saito H, Asami T, Ohwada S, Ko GT, Wong CK, Leung GT, Lee KF, Yeung CY, Chan JC. A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes. Diabetes Obes Metab. 2011 Sep;13(9):806–13. doi: 10.1111/j.1463-1326.2011.01411.x. PMID: 21492364.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b5ec48fabed55e8aff6ef016c5f16e02
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a66817aa50ba5b48bb943a35f3c9e839
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_47aa5cd683cf5ca266d892decd9fa15c
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_108e618e49d23a0afcba8556c2bad950
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_becc8e16f3e1960f17759b1081fef2c8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6437d467f4c3bbbded98a0ca5ed35a49
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7fd85bc99233d7d13ca0b460bb821571
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_9403288810aef5853485d499a7e2a479
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8647e85d28361d6adc1991f7fe080553
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0f359854bdfca3492f8986eb801a8854
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7a5c2e69c7696fc162bc182104c04e43
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dfd8a3907c39d8c5d2cb3b98dbf19a09
date 2011-07-26-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/21492364
https://doi.org/10.1111/j.1463-1326.2011.01411.x
isPartOf http://rdf.ncbi.nlm.nih.gov/pubchem/journal/22008
https://portal.issn.org/resource/ISSN/1462-8902
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title A randomized-controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose-lipid control in type 2 diabetes
discusses http://id.nlm.nih.gov/mesh/M0010903
http://id.nlm.nih.gov/mesh/M0010114
http://id.nlm.nih.gov/mesh/M0199114
http://id.nlm.nih.gov/mesh/M0002696
http://id.nlm.nih.gov/mesh/M0168845
http://id.nlm.nih.gov/mesh/M0511951
http://id.nlm.nih.gov/mesh/M0447306
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4829
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5437
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5460048
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7548
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7444
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3055168
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5793
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5997

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128121087
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129621433
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128240590
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID136164819
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID310265108
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128635168

Total number of triples: 50.